Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27260198 | 0.79 | APEX1 (0.33) | TDP1 | |
| SCHEMBL29646281 | 0.79 | CYP2A6 (0.39) | TDP1 | |
| SCHEMBL358557 | 0.79 | CYP2A6 (0.39) | TDP1 | |
| Formaldehyde SCHEMBL27993197 | 0.76 | HSP90AA1 (0.35) | TDP1 | |
| SCHEMBL27534281 | 0.75 | CYP2A6 (0.36) | TDP1 | |
| SCHEMBL30555886 | 0.75 | CYP2A6 (0.36) | TDP1 | |
| SCHEMBL30555943 | 0.75 | CYP2A6 (0.36) | TDP1 | |
| Methane SCHEMBL28608338 | 0.75 | CYP2A6 (0.36) | TDP1 | |
| SCHEMBL5319019 | 0.75 | CA1 (0.40) | TDP1 | |
| SCHEMBL10736045 | 0.75 | GAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113083032-B | Positively charged blended ultrafiltration membrane and preparation method thereof | 贵州省材料产业技术研究院 | 2022-10-28 | — | — | CN | claimed |
| CN-113083032-A | Positively charged blended ultrafiltration membrane and preparation method thereof | 贵州省材料产业技术研究院 | 2021-07-09 | — | — | CN | claimed |
| US-7312290-B2 | Curable formulations, cured compositions, and articles derived thereform | GENERAL ELECTRIC COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| EP-1799728-A1 | CURABLE FORMULATIONS, CURED COMPOSITIONS, AND ARTICLES DERIVED THEREFROM | General Electric Company (US) | 2007-06-27 | — | — | EP | claimed |
| US-7087659-B2 | Curable (meth)acrylate compositions | GENERAL ELECTRICAL (US) | 2006-08-08 | — | — | US | claimed |
| WO-2006036489-A1 | CURABLE FORMULATIONS, CURED COMPOSITIONS, AND ARTICLES DERIVED THEREFORM | GENERAL ELECTRIC COMPANY (US) | 2006-04-06 | — | — | WO | claimed |
| US-20060069222-A1 | Curable formulations, cured compositions, and articles derived thereform | GENERAL ELECTRIC COMPANY | 2006-03-30 | — | — | US | claimed |
| US-20040242720-A1 | Curable (meth)acrylate compositions | CITIBANK, N.A., AS COLLATERAL AGENT | 2004-12-02 | — | — | US | claimed |
| US-6184323-B1 | FOR OPHTHALMIC LENSES | ESSILOR INTERNATIONAL-COMPAGNIE GENERALE D'OPTIQUE (FR) | 2001-02-06 | — | — | US | claimed |
| EP-0745621-B1 | Polymerisable composition based on thio(meth)acrylate monomer, transparent polymer compositions and their optical use | ESSILOR INT (FR) | 1998-04-15 | — | — | EP | claimed |
| EP-0745621-A1 | Polymerisable composition based on thio(meth)acrylate monomer, transparent polymer compositions and their optional use | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 1996-12-04 | — | — | EP | claimed |
| US-5214116-A | Acrylic polymers with thioester group, lenses, optical fibers, optical recording media | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1993-05-25 | — | — | US | claimed |
| CN-114213333-B | Thiol compound, method for synthesizing same, and use of thiol compound | 四国化成工业株式会社 | 2024-06-25 | — | — | CN | disclosed |
| CN-118201912-A | Thiophene compound, synthesis method thereof and composition containing thiophene compound | 四国化成工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| EP-3998252-B1 | THIOL COMPOUNDS, SYNTHESIS METHOD THEREFOR, AND UTILIZATION OF SAID THIOL COMPOUNDS | SHIKOKU CHEM (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-11807596-B2 | Thiol compounds, synthesis method therefor, and utilization of said thiol compounds | SHIKOKU CHEMICALS CORPORATION (JP) | 2023-11-07 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4301088-A | Method of preparing benzyl alcohols by decarbonylation of formic acid esters | DYNAMIT NOBEL AG (DE) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807596-B2 | Thiol compounds, synthesis method therefor, and utilization of said thiol compounds | TMT1A, CTH, SLC7A11 | TDP1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.